The new findings come from a 15-year study examining the natural course of C-peptide in children and adolescents with type 1 diabetes (T1D). A marker of pancreatic function in patients with diabetes ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Early near normal glucose levels did not prevent loss of ...

Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...

The study covered in this summary was published in Research Square as a preprint and has not yet been peer reviewed. Nearly two thirds of Brazilian study participants with childhood-onset type 1 ...

Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been ...